NERV
NASDAQ · Biotechnology
Minerva Neurosciences Inc
$5.29
-0.21 (-3.82%)
Open$5.44
Previous Close$5.50
Day High$5.53
Day Low$5.22
52W High$12.46
52W Low$1.30
Volume—
Avg Volume114.0K
Market Cap254.84M
P/E Ratio—
EPS$-29.10
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
-23.8% upside
Current
$5.29
$5.29
Target
$4.03
$4.03
$3.03
$4.03 avg
$5.66
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.71M | 21.78M | 21.76M |
| Net Income | 4.38M | 3.81M | 4.44M |
| Profit Margin | 20.2% | 17.5% | 20.4% |
| EBITDA | 6.15M | 6.17M | 6.37M |
| Free Cash Flow | 3.82M | 4.48M | 4.63M |
| Rev Growth | +1.1% | -8.2% | +18.1% |
| Debt/Equity | 0.50 | 0.50 | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |